Pharmacology of moxonidine, an I1-imidazoline receptor agonist

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 3, 1996, Pages

  Ziegler, D ^a   Haxhiu, M A ^b   Kaan, E C ^a   Papp, J G ^c   Ernsberger, P ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Hypertension; I1 Receptors; Moxonidine; Review; Rostroventrolateral medulla oblongata; 2 Adrenergic receptors

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ANTIHYPERTENSIVE AGENT; CLONIDINE; EFAROXAN; GUANABENZ; IDAZOXAN; IMIDAZOLINE I1 RECEPTOR AGONIST; MOXONIDINE; OUABAIN; RAUWOLSCINE; RILMENIDINE; UNCLASSIFIED DRUG; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BINDING SITE; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE METABOLISM; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRACISTERNAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RESPIRATION DEPRESSION; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; CAT; DOG; DRUG EFFECT; DRUG POTENTIATION; HEART RATE; PATHOPHYSIOLOGY; RABBIT; RENOVASCULAR HYPERTENSION; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CATS; DOGS; HEART RATE; HYPERTENSION, RENOVASCULAR; IMIDAZOLES; RABBITS; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, DRUG;

EID: 0029835162     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199627003-00005     Document Type: Conference Paper

References (52)

1. Houston MC. The management of hypertension and associated risk factors for the prevention of long-term cardiac complications. J Cardiovasc Pharmacol 1993;21(suppl 2):S2-13.
2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Lancet 1990;335:827-38.
3. Houston MC. New insights and approaches to reduce endorgan damage in the treatment of hypertension: subsets of hypertension approach. Am Heart J 1992;123:1337-67.
4. Armah BI, Hofferber E, Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Drug Res 1988;38:1426-34.
5. Rupp H, Turcani M, Jacob R. Caloric intake and radio tele- metrically assessed high blood pressure. Pharm Pharmacol Lett 1993;3:103-6.
6. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Discontinuation syndrome after continuous infusion of clonidine in the spontaneously hypertensive rat. Life Sci 1981;28:2103-9.
7. Thoolen MJMC, Hendriks JCA, Timmermans PBMWM, van Zwieten PA. Precipitaion by yohimbine of the withdrawal syndromes of clonidine, guanfacine and methyldopa in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1983;5:224-8.
8. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat. Naunyn Schmiedebergs Arch Pharmacol 1982;319:82-6.
9. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994;24(suppl 1):S16-24.
10. Webster J, Koch HF. Rebound and aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996;27(suppl 3):S49-54 (this issue).
11. Mall G, Greber D, Gharehbaghi H, Wiest G, Amann K, Mattfeldt T. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR) -stereological studies on myocytes, capillaries, arteries and cardiac interstitium. Bas Res Cardiol 1991;86(suppl 3):33-44.
12. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. Am J Hypertens 1992;5:437-43.
13. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther [in press].
14. van Zwieten PA. Centrally induced hypotension by 2-(2,6-dichlorphenyl)-5,6-dihydroimidazo (2,1-b)-thiazole (compound 44-549). Pharmacology 1975;13:352-5.
15. 1-imidazoline agonist. Cardiovasc Drug Ther 1994:8(suppl 1):27-41.
16. 1-imidazoline agonist moxonidine administered into the rostal ventrolateral medulla. J Cardiovasc Pharmacol 1992;20(suppl 4):S11-5.
17. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994;24(suppl 1):S1-8.
18. 2-receptors in the hypotensive effect of clonidine. Nature 1976;259:587-8.
19. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-6.
20. 1-imidazoline sites. J Pharmacol Exp Ther 1993;264:172-82.
21. 2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Drug Res 1988;38:1435-42.
22. 2-adrenergic receptors. Am J Hypertens 1989;2:468-70.
23. 3H]idazoxan in rat brain. J Pharmacol Exp Ther 1989;241:1092-8.
24. 1imidazoline receptors. J Pharmacol Exp Ther [submitted].
25. Chan CKS, Sannajust F, Head GA. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J Pharmacol Exp Ther [submitted].
26. Head GA. Central monoamine systems and new antihypertensive agents. Clin Exp Hypertens 1995;17:141-52.
27. 1 receptors in the ventrolateral medulla and their role in cardiorespiratory control. Adv Lung Biol 1995;82:319-58.
28. Szabo B, Urban R, Starke K. Mechanism of sympathoinhibition by imidazolines. Ann NY Acad Sci 1995;763:552-65.
29. 1-imidazoline receptor agonist, moxonidine. Br J Pharmacol 1994;112:1089-94.
30. 1-imidazoline preferring receptors: two unique sites mediating natriuresis in the rat. Cardiovasc Drugs Ther 1994;8:43-8.
31. Li P, Penner SB, Smyth DD. Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats. Br J Pharmacol 1994;112:200-6.
32. Allan DR, Penner SB, Smyth DD. Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 1993;108:870-5.
33. Julius S, Gudbrandsson T. Early association of sympathetic overactivity. hypertension, insulin resistance and coronary risk. J Cardiovasc Pharmacol 1992;20(suppl 8):S40-8.
34. Tuck ML. Obesity, the sympathetic nervous system and essential hypertension. Hypertension 1992;19(suppl I):I-67-77.
35. Kiowski W, Osswald S. Cicadian variation of ischemic cardiac events. J Cardiovasc Pharmacol 1993;21(suppl 2):S45-8.
36. Lepran I, Papp JG. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994;24(suppl 1):S9-15.
37. 1-imidazoline receptor modulator moxonidine on experimentally-induced cardiac arrhythmia (CA). Naunyn Schmiedebergs Arch Pharmacol 1995;351:R108.
38. Azhkenazi S, Mimouni M, Laron Z, Varsano I. Asthmatic attack associated with oral clonidine test. Eur J Pediatr 1984;142:125.
39. Kales A, Bixler EO, Cadieux RJ, et al. Sleep apnoea in a hypertensive population. Lancet 1984;2:1005-8.
40. 1-imidazoline receptor activation on responses of hypoglossal and phrenic nerve to chemical stimulation. Ann NY Acad Sci 1995;763:445-62.
41. Hjermann I. The metabolic cardiovascular syndrome: syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol 1992;20(suppl 8):S5-10.
42. Kjeldsen SE, Rostrup M, Moan A, Mundal HH, Gjesdal K, Eide IK. The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension. J Cardiovasc Pharmacol 1992;20(suppl 8):S32-9.
43. Björntorp P. Abdominal fat distribution and the metabolic syndrome. J Cardiovasc Pharmacol 1992;20(suppl 8):S26-8.
44. Lind L, Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia and hyperinsulinemia. Am Heart J 1993;125:1494-7.
45. Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991;9:983-6.
46. Landsberg L. Diabetes. Obesity and hypertension: role of insulin and the sympathetic nervous system. Cardiovasc Risk Factors 1993;3:153-8.
47. Landsberg L. Pathophysiology of obesity-related hypertension: role of insulin and the sympathetic nervous system. J Cardiovasc Pharmacol 1994;23(suppl 1):S1-8.
48. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med Hypothesis 1995;44:217-25.
49. Koletsky RJ, Ernsberger P. Obese SHR (Koletsky rat): a model for the interactions between hypertension and obesity. Colloq INSERM 1992;218:373-5.
50. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, Ziegler D. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995;5:19-27.
51. 1-imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. Br J Pharmacol 1995;114:751-4.
52. Ogidigben M, Chu TH, Potter DE. Ocular actions of moxonidine: a possible role for imidazoline receptors. J Pharmacol Exp Ther 1994;269:897-904.